UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K/A

Amendment #1

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2023

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from   to

 

Commission file number: 001-40927

 

ZEO ENERGY CORP.

(Exact name of registrant as specified in its charter)

 

Delaware   98-1601409
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

7625 Little Rd, Suite 200A,

New Port Richey, FL

 

34654

(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (727) 375-9375

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A Common Stock, par value $0.0001 per share   ZEO   The Nasdaq Stock Market LLC
Warrants, each exercisable for one share of Class A Common Stock at a price of $11.50, subject to adjustment   ZEOWW   The Nasdaq Stock Market LLC

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer 

  Accelerated filer    Non-accelerated filer    Smaller reporting company   Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

 

As of June 30, 2023, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the Class A ordinary shares outstanding, other than shares held by persons who may be deemed affiliates of the registrant, computed by reference to the closing sales price for the Class A ordinary shares on June 30, 2023, as reported on Nasdaq, was $31,514,518.40 (based on the closing sales price of the Class A ordinary shares on June 30, 2023 of $10.88).

 

As of March 25, 2024, 5,026,964 shares of Class A Common Stock, par value $0.0001, were issued and outstanding and 35,230,000 shares of Class V Common Stock, par value $0.0001, were issued and outstanding.

 

Documents Incorporated by Reference

 

Not applicable.

 

 

 

 

 

 

EXPLANATORY NOTE

 

The purpose of this Amendment No. 1 to Zeo Energy Corp.’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 25, 2024 (the “Form 10-K”), is being filed with the limited purpose of amending the Report of Independent Registered Public Accounting Firm on page F-1 to correct a scrivener’s error with respect to the omission of the city and state thereof. No other changes have been made to the Form 10-K. This Amendment No. 1 to the Form 10-K speaks as of the original filing date of the Form 10-K, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-K.

 

 

 

 

TABLE OF CONTENTS

 

PART II  
   
ITEM 8. FINANCIAL STATEMENT AND SUPPLEMENTARY DATA 1
   
PART IV  
   
ITEM 15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES 1

  

i

 

 

PART II

 


ITEM 8. FINANCIAL STATEMENT AND SUPPLEMENTARY DATA.

 

This information appears following Item 15 of this Report and is incorporated herein by reference.

 

PART IV

 

ITEM 15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES.

 

The following documents are filed as part of this Form 10-K:

 

(1) Financial Statements: Our financial statements are listed in the “Index to Financial Statements” on page F-1.

 

(2) Financial Statement Schedules: None.

 

1

 

 

(3) Exhibits

 

We hereby file as part of this Report the exhibits listed in the attached Exhibit Index. Copies of such material can also be obtained on the SEC website at www.sec.gov.

 

Exhibit       Incorporated by Reference
Number   Description   Form   Exhibit   Filing Date
2.1   Business Combination Agreement, dated as of April 19, 2023, by and among ESGEN, Sunergy, the Sellers, OpCo, the Sponsor and Timothy Bridgewater.   8-K   2.1   April 20, 2023
2.2   Amendment No. 1 to Business Combination Agreement, dated as of January 24, 2024, by and between ESGEN and Sunergy.   8-K   2.1   January 25, 2024
3.1   Certificate of Incorporation of Zeo Energy Corp.   8-K   3.1   March 20, 2024
3.2   Bylaws of Zeo Energy Corp.   8-K   3.2   March 20, 2024
10.1   Amended and Restated Subscription Agreement, dated as of January 24, 2024, by and among ESGEN, OpCo and the Sponsor.   8-K   10.2   January 25, 2024
10.2   Letter Agreement, dated as of October 22, 2021, by and among ESGEN, the Sponsor and the Insiders party thereto.   8-K   10.5   October 25, 2021
10.3   Amendment to Letter Agreement, dated as of April 19, 2023, by and among ESGEN, the Sponsor and the Insiders party thereto.   8-K   10.1   April 20, 2023
10.4   Amendment No. 2 to Letter Agreement, dated as of January 24, 2024, by and among ESGEN, the Sponsor and the Insiders party thereto.   8-K   10.1   January 25, 2024
10.5   Side Letter, dated as of March 13, 2024 by and among ESGEN, Sponsor, Sunergy and the other parties thereto.   8-K   10.5   March 20, 2024
10.6   Non-Redemption Agreement, dated as of March 11, 2024, by and between ESGEN and The K2 Principal Fund L.P.   8-K   10.1   March 12, 2024
10.7   Amended and Restated Registration Rights Agreement, dated as of March 13, 2024.   8-K   10.7   March 20, 2024
10.8   OpCo A&R LLC Agreement, dated as of March 13, 2024.   8-K   10.8   March 20, 2024
10.9   Form of Lock-Up Agreement.   8-K   2.1   April 20, 2023
10.10   Tax Receivable Agreement, dated as of March 13, 2024.   8-K   10.10   March 20, 2024
10.11   Form of Indemnification Agreement.   8-K   10.11   March 20, 2024
10.12   Employment Agreement, dated March 13, 2024, by and between Opco and Timothy Bridgewater.   8-K   10.12   March 20, 2024
10.13   Employment Agreement, dated March 13, 2024, by and between Opco and Kalen Larsen.   8-K   10.13   March 20, 2024
10.14   Employment Agreement, dated March 13, 2024, by and between Opco and Gianluca “Luke” Guy.   8-K   10.14   March 20, 2024
10.15   Employment Agreement, dated March 13, 2024, by and between Opco and Brandon Bridgewater.   8-K   10.15   March 20, 2024
10.17   Zeo Energy Corp. 2024 Omnibus Incentive Equity Plan.   8-K   10.17   March 20, 2024
21.1   Subsidiaries of Zeo Energy Corp.   10-K   21.1  

March 25, 2024

31*   Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.            
32**   Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.            
97   Clawback Policy.  

10-K

 

97

 

 March 25, 2024

101*   Interactive data file set for the financial statements and accompanying notes contained in this Report (formatted as Inline XBRL).            
104*   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).            

 

 
*Filed herewith
**Furnished herewith

 

ITEM 16. FORM 10-K SUMMARY.

 

None.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized this date of April 1, 2024.

 

  Zeo Energy Corp.
     
  By: /s/ Timothy Bridgewater
  Name:  Timothy Bridgewater
  Title: Chief Executive Officer and Chief Financial Officer

 

Name   Position
     
/s/ Timothy Bridgewater   Chief Executive Officer and Chief Financial
  Officer (Principal Executive Officer, Principal Financial Officer and Principal
  Accounting Officer)
     
/s/ Gianluca “Luke” Guy   Director
Gianluca “Luke” Guy    
     
/s/ Dr. Abigail M. Allen   Director
Dr. Abigail M. Allen    
     
/s/ James P. Benson   Director
James P. Benson    
     
/s/ Neil Bush   Director
Neil Bush    
     
/s/ Mark Jacobs   Director
Mark Jacobs    

 

3

 

 

ESGEN ACQUISITION CORPORATION

INDEX TO FINANCIAL STATEMENTS

 

    Page
Report of Independent Registered Public Accounting Firm (BDO USA, P.C., New York, NY, PCAOB ID#243)   F - 2
     
Balance Sheets as of December 31, 2023 and 2022   F - 3
     
Statements of Operations for the years ended December 31, 2023 and 2022   F - 4
     
Statements of Changes in Redeemable Ordinary Shares and Shareholders’ Deficit for the years ended December 31, 2023 and 2022   F - 5
     
Statements of Cash Flows for the years ended December 31, 2023 and 2022   F - 6
     
Notes to Financial Statements   F - 7 to F - 23

 

F-1

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

Shareholders and Board of Directors

ESGEN Acquisition Corporation

Dallas, Texas

 

Opinion on the Financial Statements

 

We have audited the accompanying balance sheets of ESGEN Acquisition Corporation (the “Company”) as of December 31, 2023, and 2022, the related statements of operations, changes in redeemable ordinary shares and shareholders’ deficit, and cash flows for each of the years then ended, and the related notes (referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position at December 31, 2023 and 2022 of the Company, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern Uncertainty

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company does not have sufficient cash and working capital to sustain its operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

  

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Emphasis of Matter - Business Combination

 

As discussed in Note 10 to the financial statements, the Company consummated the business combination discussed in Note 6 on March 13, 2024.

 

/s/ BDO USA, P.C.

 

We have served as the Company’s auditor since 2021.

 

March 25, 2024

New York, New York

 

F-2

 

 

ESGEN ACQUISITION CORPORATION

BALANCE SHEETS

 

   December 31,
2023
   December 31,
2022
 
Assets          
Current assets:          
Cash  $60,518   $614,767 
Prepaid expenses   19,279    31,110 
Total current assets   79,797    645,877 
Non-current assets:          
Marketable securities and cash held in Trust Account   16,018,732    285,506,568 
Total assets  $16,098,529   $286,152,445 
Liabilities,  Redeemable  Ordinary Shares  and Shareholders’ Deficit          
Current liabilities:          
Accounts payable and accrued expenses  $5,669,349   $1,866,992 
Due to related party   339,193    144,193 
Promissory note-related party   1,783,744    171,346 
Total current liabilities   7,792,286    2,182,531 
Non-current liabilities:          
Warrant liabilities   1,113,600    796,224 
Deferred underwriters fee   
-
    9,660,000 
Total liabilities  $8,905,886   $12,638,755 
Commitments and Contingencies   
 
    
 
 
Class A ordinary shares subject to possible redemption, $0.0001 par value; 1,408,555 and 27,600,000 shares at redemption value as of December 31, 2023 and 2022, respectively   16,018,732    285,506,568 
Shareholders’ Deficit:          
Preferred shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding   
-
    
-
 
Class A shares, $0.0001 par value; 250,000,000 shares authorized; 5,619,077 and 0 issued or outstanding (excluding 1,408,555 and 27,600,000 shares subject to possible redemption) as of December 31, 2023 and 2022, respectively   562    
-
 
Class B shares, $0.0001 par value; 25,000,000 shares authorized; 1,280,923 and 6,900,000 shares issued and outstanding, respectively   128    690 
Accumulated deficit   (8,826,779)   (11,993,568)
Total shareholders’ deficit   (8,826,089)   (11,992,878)
Total Liabilities, Redeemable Ordinary Shares and Shareholders’ Deficit  $16,098,529   $286,152,445 

 

The accompanying notes are an integral part of these financial statements.

 

F-3

 

 

ESGEN ACQUISITION CORPORATION

STATEMENTS OF OPERATIONS

 

   Year Ended
December 31,
   Year Ended
December 31,
 
   2023   2022 
Legal and professional fees  $4,343,626   $1,913,373 
Insurance   92,103    528,861 
Other operating costs   503,396    267,883 
Operating cost-related party   120,000    120,000 
Loss from operations   (5,059,125)   (2,830,117)
Other income (expense):          
Change in fair value of warrants liabilities   (317,376)   13,179,936 
Interest and investment income on marketable securities and cash held in Trust Account   1,950,267    3,984,431 
Recovery of deferred offering costs allocated to warrants   425,040    
-
 
Total other income, net   2,057,931    17,164,367 
Net (loss) income  $(3,001,194)  $14,334,250 
Basic and diluted weighted average shares outstanding of redeemable Class A ordinary shares
   3,821,284    27,600,000 
Basic and diluted  net (loss) income per share, redeemable Class A
  $(1.32)  $0.44 
Basic and diluted weighted average shares outstanding of non-redeemable Class A and Class B ordinary shares
   6,900,000    6,900,000 
Basic and diluted  net income per share, non-redeemable Class A and Class B
  $0.29   $0.30 

 

The accompanying notes are an integral part of these financial statements.

 

F-4

 

 

ESGEN ACQUISITION CORPORATION

 

STATEMENTS OF CHANGES IN REDEEMABLE ORDINARY SHARES AND SHAREHOLDERS’ DEFICIT

FOR THE YEAR ENDED DECEMBER 31, 2023 AND 2022

 

   Class A Ordinary
share subject to possible
   Class A   Class B   Additional       Total 
   redemption   Ordinary share   Ordinary share   Paid-in   Accumulated   Shareholder’ 
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Deficit 
Balance as of December 31, 2021   27,600,000   $281,520,000    
-
   $
-
    6,900,000   $690   $
-
   $(22,341,250)  $(22,340,560)
Accretion of ordinary shares subject to possible redemption   -    3,986,568    -    
-
    -    
-
    
-
    (3,986,568)   (3,986,568)
Net income   -     -    -    
-
    -    
-
    
-
    14,334,250    14,334,250 
Balance as of December 31, 2022   27,600,000    285,506,568    -    
-
    6,900,000    690    
-
    (11,993,568)   (11,992,878)
Redemption of Class A ordinary shares subject to possible redemption   (26,194,445)   (272,554,813)   
-
    
-
    
-
    
-
    
-
    
-
    
-
 
Recovery of deferred offering costs   -    
-
    -    
-
    -    
-
    
-
    9,234,960    9,234,960 
Conversion of Class B ordinary shares to Class A ordinary shares   -    
-
    5,619,077    562    (5,619,077)   (562)   
-
    
-
    
-
 
Accretion of ordinary shares subject to possible redemption   -    3,066,977    -    
-
    -    
-
    
-
    (3,066,977)   (3,066,977)
Net loss   -    
-
    -    
-
    -    
-
    
-
    (3,001,194)   (3,001,194)
Balance as of December 31, 2023   1,405,555   $16,018,732    5,619,077   $562    1,280,923   $128   $
-
   $(8,826,779)  $(8,826,089)

 

The accompanying notes are an integral part of these financial statements.

 

F-5

 

 

ESGEN ACQUISITION CORPORATION

STATEMENTS OF CASH FLOWS

 

   For the year ended   For the year ended 
   December 31,
2023
   December 31,
2022
 
Cash flows from operating activities:          
Net (loss) income  $(3,001,194)  $14,334,250 
Adjustments to reconcile net (loss) income to net cash provided by in operating activities:          
Recovery of deferred offering costs allocated to warrants   (425,040)   
-
 
Change in fair value of warrant liabilities   317,376    (13,179,936)
Changes in operating assets and liabilities:          
Due to related party   195,000    545,405 
Prepaid assets   11,831    1,455,576 
Accounts payable and accrued expenses   3,802,357    120,000 
Net cash provided by operating activities   900,330    3,275,295 
Cash Flows from Investing Activities:          
Extension funding used to purchase marketable securities and cash held in Trust Account   (1,116,710)   
-
 
Cash withdrawn from Trust Account in connection with redemptions   272,554,813    
-
 
Proceeds from sale of marketable securities deposited into cash held in Trust Account   15,862,501    
-
 
Reinvestment of marketable securities and cash held in Trust Account   (1,794,036)   (3,984,431)
Net cash provided by (used in) investing activities   285,506,568    (3,984,431)
Cash flows from financing  activities:          
Proceeds from note payable-related party   1,612,398    
-
 
Redemptions of Class A ordinary shares subject to possible redemption   (272,554,813)   
-
 
Net cash used in financing  activities   (270,942,415)   
-
 
Net change in cash  $15,464,483   $(709,136)
Cash, beginning of the period  $614,767   $1,323,903 
Cash, end of the period  $60,518   $614,767 
Cash held in Trust Account   16,018,732    
-
 
Total cash and cash in Trust Account  $16,079,250   $614,767 
Supplemental disclosure  of cash flow information:          
Change in value of Class A ordinary shares subject to possible redemption  $3,066,977   $3,986,568 
Impact of the waiver of deferred commission by the underwriters  $9,234,960   $
-
 
Conversion of Class B ordinary shares to Class A ordinary shares  $562   $
-
 

 

The accompanying notes are an integral part of these financial statements.

 

F-6

 

 

ESGEN ACQUISITION CORPORATION

NOTES TO FINANCIAL STATEMENTS

 

Note 1 - Organization and Business Operation

 

ESGEN Acquisition Corporation (the “Company” or “ESGEN”) was incorporated as a Cayman Islands exempted company on April 19, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”). The Company will not be limited to a particular industry or geographic region in its identification and acquisition of a target company. The Company consummated the Business Combination on March 13, 2024 (see Note 10 – Subsequent Events).

 

As of December 31, 2023, the Company had not commenced any operations. All activity for the period from April 19, 2021 (inception) through December 31, 2023, relates to the Company’s formation and the initial public offering (“Public Offering” or “IPO”) described below and since the closing of the IPO, the search for a prospective initial Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest or dividend income on cash and cash equivalents from the proceeds derived from the Public Offering (as defined below).

 

The Company’s sponsor is ESGEN LLC, a Delaware limited liability company (the “Sponsor”).

 

The registration statement for the Company’s IPO was declared effective on October 19, 2021. On October 22, 2021, the Company consummated its IPO of 27,600,000 units (the “Units” and, with respect to the ordinary shares included in the Units being offered, the “public shares”) at $10.00 per Unit and the sale of 14,040,000 warrants (the “Private Placement Warrants”) each exercisable to purchase one Class A ordinary share at $11.50 per share, at a price of $1.00 per Private Placement Warrant in a private placement to the Sponsor that closed simultaneously with the Public Offering.

 

The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (as defined below) (excluding the deferred underwriters fee and taxes payable on the interest or dividends earned on the Trust Account) at the time of signing a definitive agreement in connection with the initial Business Combination. However, the Company will complete the initial Business Combination only if the post-Business Combination company in which its public shareholders own shares will own or acquire 50% or more of the outstanding voting securities of the target or is otherwise not required to register as an investment company under the Investment Company Act (the “Investment Company Act”). There is no assurance that the Company will be able to complete a Business Combination successfully.

 

Following the closing of the IPO on October 22, 2021, $281,520,000 ($10.20 per Unit) from the net proceeds sold in the IPO, including proceeds of the sale of the Private Placement Warrants, was deposited in a trust account (“Trust Account”) and, until October 16, 2023, was only invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations. To mitigate the risk of being deemed to have been operating as an unregistered investment company under the Investment Company Act, on October 16, 2023, the Company instructed the Trustee with respect to the Trust Account, to liquidate the U.S. government securities or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in demand deposits (i.e., in one or more bank accounts) until the earliest of ESGEN’s completion of an initial business combination or July 22, 2024 (assuming the Sponsor deposits the required amount into the Trust Account for each New Additional Extension Date and unless the Company’s shareholders approve one or more further Additional Extensions).

 

F-7

 

 

Except with respect to interest or other income earned on the funds held in the Trust Account that may be released to the Company to pay its income taxes, if any, the amended and restated memorandum and articles of association, as discussed below and subject to the requirements of law and regulation, will provide that the proceeds from the Public Offering and the sale of the Private Placement Warrants held in the Trust Account will not be released from the Trust Account (1) to the Company, until the completion of the initial Business Combination, or (2) to the public shareholders, until the earliest of (a) the completion of the initial Business Combination, and then only in connection with those Class A ordinary shares that such shareholders properly elected to redeem, subject to the limitations described herein, (b) the redemption of any public shares properly tendered in connection with a shareholder vote to amend the amended and restated memorandum and articles of association (A) to modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the public shares if the Company did not complete its initial Business Combination within 15 months (which was extended pursuant to shareholder approval of the Charter Amendment (as defined below)) from the closing of this offering (the “Combination Period”) or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares, and (c) the redemption of the public shares if the Company has not consummated the Business Combination within Combination Period, subject to applicable law. Public shareholders who redeem their Class A ordinary shares in connection with a shareholder vote described in clause (b) in the preceding sentence shall not be entitled to funds from the Trust Account upon the subsequent completion of an initial Business Combination or liquidation if the Company has not consummated an initial Business Combination within Combination Period, with respect to such Class A ordinary shares so redeemed.

 

The Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a proposed Business Combination or conduct a tender offer will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require the Company to seek shareholder approval under applicable law or stock exchange listing requirement.

 

The Company will provide its public shareholders with the opportunity to redeem all or a portion of their Class A ordinary shares upon the completion of its initial Business Combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial Business Combination, including interest or dividends earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any, divided by the number of then-outstanding public shares, subject to the limitations described herein. The amount in the Trust Account is initially $10.20 per public share. The per share amount the Company will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriters fee the Company will pay to the underwriters.

 

The ordinary shares subject to redemption were recorded at redemption value and classified as temporary equity upon the completion of the Public Offering, in accordance with Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination.

 

The Company has until July 22, 2024 (assuming the Sponsor deposits the required amount into the Trust Account for each New Additional Extension Date and unless the Company’s shareholders approve one or more further Additional Extensions), to consummate the initial Business Combination. If the Company has not consummated the initial Business Combination within the Combination Period, the Company will: (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest or dividends earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000 of interest or dividends to pay winding up and dissolution expenses) divided by the number of the then-outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and its board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.

 

F-8

 

 

On January 18, 2023, the Company held an extraordinary general meeting of shareholders to consider and vote upon, among other things, a proposal to amend the Company’s amended and restated memorandum and articles of association (the “First Extension Charter Amendment”) to (i) extend the date by which the Company must consummate its initial Business Combination (the “Termination Date”) from January 22, 2023 to April 22, 2023 and (ii) in the event that the Company has not consummated an initial business combination by April 22, 2023, to allow the Company, by resolution of the Company’s board of directors (the “Board”) and, without any approval of the Company’s shareholders, upon five days’ advance notice prior to each Additional Extension, to extend the Termination Date up to six times (with each such extension being upon five days’ advance notice), each by one additional month (for a total of up to six additional months to complete a business combination) (each, an “Additional Extension” and such date, the “Additional Extension Date”), provided that the Sponsor or the Sponsor’s affiliates or permitted designees will deposit into the Trust Account for each Additional Extension Date the lesser of (a) $140,000 or (b) $0.04 for each public share that is then-outstanding, in exchange for one or more non-interest bearing, unsecured promissory notes issued by the Company to the Sponsor or the Sponsor’s affiliates or permitted designees (the “Lenders” and each a “Lender”). In connection with the vote to approve the First Extension Charter Amendment, the holders of 24,703,445 Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.35 per share, for an aggregate redemption amount of $255,875,758.

 

The Sponsor and each member of the management team have entered into an agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their Founder Shares; (ii) waive their redemption rights with respect to their Founder Shares and public shares in connection with a shareholder vote to approve an amendment to the Company’s amended and restated memorandum and articles of association (A) that would modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the public shares if the Company did not complete its initial Business Combination within 15 months from the closing of the Public Offering (which was extended pursuant to shareholder approval of the Charter Amendment) or (B) with respect to any other provision relating to the rights of holders of the Company’s Class A ordinary shares and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to consummate an initial Business Combination within Combination Period.

 

The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company (other than the Company’s independent registered public accounting firm), or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per public share due to reductions in the value of the Trust Account, in each case net of the interest or dividends that may be withdrawn to pay the Company’s income tax obligations, provided that such liability will not apply to any claims by a third party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believe that the Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure you that the Sponsor would be able to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses.

 

On October 20, 2023, at the Company’s extraordinary general meeting, the shareholders approved, among other proposals, (i) (a) the extension (such proposal, the “Extension Proposal”) of the time period the Company has to complete an initial Business Combination from October 22, 2023 to January 22, 2024 (the “Charter Amendment”) and (b) in the event that the Company has not consummated an initial Business Combination by January 22, 2024, to allow the Company, by resolution of the Board and, without any approval of the Company’s shareholders, upon five days’ advance notice prior to each Additional Extension, to complete six Additional Extensions, provided that the Sponsor or the Sponsor’s affiliates or permitted designees will deposit into the Trust Account for each Additional Extension Date the lesser of (x) $35,000 or (y) $0.0175 for each public share that is then-outstanding, in exchange for one or more non-interest bearing, unsecured promissory notes issued by a Lender, and (ii) the amendment of the Company’s amended and restated memorandum and articles of association to change certain provisions which restrict the Class B ordinary shares, par value $0.0001, of the Company (the “Class B ordinary shares”) from converting to Class A ordinary shares, par value $0.0001 (the “Class A ordinary shares”) prior to the consummation of an initial Business Combination (such proposal, the “Conversion Proposal”). As of the date of filing this report, the Company has deposited the requisite amounts into the Trust Account for each Additional Extension Date until March 22, 2024.

 

F-9

 

 

Additionally, the shareholders approved a proposal to amend, by special resolution, the Company’s amended and restated memorandum and articles of association to change certain provisions which restrict the Class B ordinary shares from converting to Class A ordinary shares prior to the consummation of an initial Business Combination.

 

In connection with the vote to approve the above proposals, the holders of 1,488,000 Class A ordinary shares of ESGEN exercised their right to redeem their shares for cash at a redemption price of approximately $11.21 per share, for an aggregate redemption amount of $16,679,055.

 

In connection with the approval of the Extension Proposal at the Meeting and the adoption of the Charter Amendment, the Sponsor contributed into the Trust Account $0.0525 per share for each Class A ordinary share that was not redeemed at the Meeting, for an aggregate contribution of $73,949.

 

In connection with the approval of the Conversion Proposal at the Meeting and the adoption of the Charter Amendment, the Sponsor converted all of its 5,619,077 Class B ordinary shares into Class A ordinary shares. As a result of the Sponsor Share Conversion and redemptions made in connection with the Extension Proposal and Conversion Proposal, 7,027,632 Class A ordinary shares remain outstanding. Notwithstanding the Sponsor Share Conversion, the Sponsor will be not entitled to receive any funds held in the Trust Account with respect to any Class A ordinary shares issued to the Sponsor as a result of the Sponsor Share Conversion and no additional amounts will be deposited into the Trust Account in respect of shares of Class A ordinary shares held by the Sponsor in connection with the extension of the Termination Date to the Extended Date or any Additional Extension Dates.

 

On October 16, 2023 (the “Compliance Date”), the Company was notified by The Nasdaq Stock Market LLC (the “Nasdaq”) that the Company was not in compliance with the minimum number of round lot holders required for continued listing on the Nasdaq Global Market (the “Round Lot Requirement”). The Company has until April 15, 2024 to comply with the Round Lot Requirement. If ESGEN does not regain compliance with the Round Lot Requirement by the Compliance Date, ESGEN will receive written notification that its securities are subject to delisting, at which time ESGEN may appeal the Nasdaq’s delisting determination to a Nasdaq Listing Qualifications Panel (the “Panel”). There can be no assurance that ESGEN will be able to regain compliance with the Round Lot Requirement or that any appeal of the Nasdaq’s delisting determination to the Panel would be successful.

 

Founder Shares

 

Founder Shares refers to the Class B ordinary shares (the “Founder Shares”) acquired by the initial shareholders prior to the Company’s IPO.

 

The initial shareholders and each member of the management team have entered into an agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their Founder Shares and public shares in connection with the completion of the Business Combination; (ii) waive their redemption rights with respect to their Founder Shares and public shares in connection with a shareholder vote to approve an amendment to the amended and restated memorandum and articles of association (A) that would modify the substance or timing of the Company’s obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the Business Combination or to redeem 100% of the Company’s public shares if it does not complete the Business Combination by the Termination Date or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to consummate an Business Combination by the Termination Date (although they will be entitled to liquidating distributions from the Trust Account with respect to any public shares they hold if the Company fails to complete the Business Combination within the prescribed time frame). If the Company seeks shareholder approval, it will complete the Business Combination only if it is approved by an ordinary resolution or such higher approval threshold as may be required by Cayman Islands law and pursuant to the amended and restated memorandum and articles of association. In such case, the initial shareholders and each member of the management team have agreed to vote their Founder Shares and public shares in favor of the Business Combination.

 

In connection with the approval of the Conversion Proposal at the Meeting and the adoption of the Charter Amendment, the Sponsor converted all of its 5,619,077 Class B ordinary shares into Class A ordinary shares (the “Sponsor Share Conversion”). As a result of the Sponsor Share Conversion and redemptions made in connection with the Extension Proposal and Conversion Proposal, 7,027,632 Class A ordinary shares remain outstanding. Notwithstanding the Sponsor Share Conversion, the Sponsor will be not entitled to receive any funds held in the Trust Account with respect to any Class A ordinary shares issued to the Sponsor as a result of the Sponsor Share Conversion and no additional amounts will be deposited into the Trust Account in respect of shares of Class A ordinary shares held by the Sponsor in connection with the extension of the Termination Date to the Extended Date or any Additional Extension Dates.

 

F-10

 

 

Risks and Uncertainties

 

The credit and financial markets have experienced extreme volatility and disruptions due to the current conflict between Ukraine and Russia. The conflict is expected to have further global economic consequences, including but not limited to the possibility of severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in inflation rates and uncertainty about economic and political stability. In addition, the United States and other countries have imposed sanctions on Russia which increases the risk that Russia, as a retaliatory action, may launch cyberattacks against the United States, its government, infrastructure and businesses. Any of the foregoing consequences, including those we cannot yet predict, may cause our business, financial condition, results of operations and the price of our ordinary shares to be adversely affected.

 

Additionally, recent military conflicts, including the Russian invasion of Ukraine, the Israel-Hamas war, and increased military tensions, may have a material adverse effect on financial and business conditions. These circumstances could reduce the number of attractive targets for an initial Business Combination, increase the cost of consummating an initial Business Combination and delay or prevent the Company from completing an initial Business Combination.

 

Going Concern

 

As of December 31, 2023, the Company had $60,518 in cash held outside of the Trust Account and owes $5,669,349 in accounts payable and accrued expenses and $2,122,937 to related parties. The Company anticipates that its cash will not be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans and the closing of the business combination described in Note 10. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

 

The Company will seek additional capital through other financing alternatives. There can be no assurance that new financings or other transactions will be available to the Company on commercially acceptable terms, or at all. Should the Company fail to raise additional cash from outside sources, this would have a material adverse impact on its operations.

 

The accompanying financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern.

 

Note 2 - Significant Accounting Policies

 

Basis of Presentation

 

The accompanying audited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements. Such financial statements and accompanying notes are the representations of the Company’s management, who is responsible for their integrity and objectivity.

 

F-11

 

 

Emerging Growth Company Status

 

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.

 

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash and cash equivalents. The Company had no cash equivalents as of December 31, 2023 and 2022, respectively.

 

Marketable Securities and Cash Held in Trust Account

 

As of December 31, 2023, investments held in the Trust Account consisted of interest bearing demand deposits. As of December 31, 2022, substantially all of the assets held in the Trust Account were held in U.S. Money Market Funds. Such investments are presented on the condensed balance sheets at fair value at the end of the reporting period. Interest, dividends, gains and losses resulting from the change in fair value of these investments are included in income from investments held in Trust Account in the accompanying condensed statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.

 

Fair Value Measurement

 

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the balance sheet, primarily due to its short-term nature.

 

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The Company’s financial instruments are classified as either Level 1, Level 2 or Level 3. These tiers include:

 

  Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;

 

  Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

F-12

 

 

  Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

Derivative Financial Instruments

 

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. The Company’s derivative instruments are recorded at fair value on the balance sheet with changes in the fair value reported in the statements of operations. Derivative liabilities are classified on the balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument is reasonably expected to require the use of existing resources properly classifiable as current assets, or the creation of other current liabilities.

 

Warrant Liabilities

 

The Company accounts for the Public and Private Placement warrants issued in connection with the Public Offering in accordance with the guidance contained in ASC Topic 815-40 and ASC Topic 480. Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company will classify each warrant as a liability at its fair value. These liabilities are subject to re-measurement at each balance sheet date. With each such re-measurement, the warrant liabilities will be adjusted to fair value, with the change in fair value recognized in the Company’s statements of operations.

 

Net (Loss) Income Per Ordinary Share

 

The Company has two classes of shares, which are referred to as redeemable Class A ordinary shares and non-redeemable Class A and Class B ordinary shares. Income and losses are shared pro rata between the two classes of shares. Net (loss) income per ordinary share is calculated by dividing the net (loss) income by the weighted average ordinary shares outstanding for the respective period. With respect to the accretion of Class A ordinary shares subject to possible redemption, the Company treated accretion in the same manner as a dividend, paid to the shareholder in the calculation of the net (loss) income per ordinary share.

 

The earnings per share presented in the statement of operations is based on the following:

 

   Year Ended
December 31,
2023
   Year Ended
December 31,
2022
 
Net (loss) income  $(3,001,194)  $14,334,250 
Accretion of temporary equity to redemption value   6,167,983    (3,984,431)
Net income including accretion of temporary equity to redemption value  $3,166,789   $10,349,819 

 

   Year Ended December 31, 2023   Year Ended December 31, 2022 
       Non-redeemable       Non-redeemable 
   Redeemable
Class A
   Class A and
Class B
   Redeemable
Class A
   Class A and
Class B
 
Basic and diluted net (loss) income per share                
Numerator:                
                 
Allocation of net (loss) income including accretion of temporary equity  $1,140,044   $2,026,745   $8,279,855   $2,069,964 
Allocation of accretion of temporary equity to redemption value   (6,167,983)   -    3,984,431    - 
Allocation of net (loss) income  $(5,027,939)  $2,026,745   $12,264,286   $2,069,964 
Denominator:                    
Weighted-average shares outstanding   3,821,284    6,900,000    27,600,000    6,900,000 
Basic and diluted net (loss) income per share
  $(1.32)  $0.29   $0.44   $0.30 

 

F-13

 

 

Net (loss) income per share is computed by dividing net (loss) income by the weighted average number of ordinary shares outstanding during the period. The Company has not considered the effect of the 27,840,000 ordinary shares issuable upon exercise of the Public Warrants and Private Placement Warrants in the calculation of diluted (loss) income per share, since the exercise of such warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.

 

Class A Ordinary Shares Subject to Possible Redemption

 

The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480. Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares sold in the IPO feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events.

 

The Company has made a policy election in accordance with ASC 480-10-S99-3A and recognizes changes in redemption value in additional paid-in capital (or accumulated deficit in the absence of additional paid-in capital) immediately as they occur. The Company recorded accretion of $3,066,977 and $3,986,568, respectively, in accumulated deficit for year ended December 31, 2023 and 2022. For the period ended December 31, 2023, the Company recorded redemption of $272,554,813 and $1,116,710 was deposited in the Trust Account for extension funding. For the year ended December 31, 2022 there were no redemptions or deposits in the Trust Account for extension funding.

 

Income Taxes

 

ASC Topic 740, “Income Taxes”, requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC Topic 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.

 

ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of December 31, 2023 and 2022.

 

The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statements.

 

F-14

 

 

The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December 31, 2023 and 2022, there were no unrecognized tax benefits and no amounts were accrued for the payment of interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

 

Recent Accounting Pronouncements

 

Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

 

Note 3 - Related Party Transactions

 

Promissory Notes - Related Party

 

On April 27, 2021, the Sponsor agreed to loan the Company up to $300,000 to be used for a portion of the expenses of the Public Offering. The Company borrowed a total of $262,268. This loan was non-interest bearing, unsecured and due at the earlier of December 31, 2021 or the closing of the Public Offering. The loan was to be repaid upon the closing of the Public Offering out of the offering proceeds not held in the Trust Account. In connection with the closing of the Public Offering, the Company paid down $90,922 of the outstanding balance. As of December 31, 2023 and 2022, the Company had $171,346 outstanding under the promissory note and as is included on the balance sheet as promissory note-related party. The Sponsor has agreed to defer repayment of the loan until the close of the Business Combination.

 

On April 5, 2023, the Company issued an unsecured promissory note (the “Note”) in the principal amount of up to $1,500,000 to the Sponsor, which may be drawn down by the Company from time to time prior to the consummation of the Company’s Business Combination. The Note does not bear interest, matures on the date of consummation of the Business Combination and is subject to customary events of default.

 

On October 17, 2023, ESGEN issued an amended and restated promissory note (the “October 2023 Promissory Note”) in the principal amount of up to $2,500,000 to the Sponsor. The October 2023 Promissory Note amends, restates, replaces and supersedes the Note dated April 5, 2023. The October 2023 Promissory Note may be drawn down by ESGEN from time to time prior to the consummation of ESGEN’s initial Business Combination. The October 2023 Promissory Note does not bear interest, matures on the date of consummation of the Business Combination and is subject to customary events of default. The October 2023 Promissory Note, as well as the promissory note issued on April 17, 2021 to the Sponsor (“April 2021 Promissory Note”), will not be repaid and will be cancelled at the closing of the Business Combination. As of December 31, 2023, the Company had $1,612,398 outstanding under the October 2023 Promissory Note and is included on the balance sheet as promissory note-related party.

 

On January 24, 2024, ESGEN issued a new promissory note (“January 2024 Promissory Note”) in the principal amount of up to $750,000 to the Sponsor. The January 2024 Promissory Note may be drawn down by ESGEN from time to time prior to the consummation of ESGEN’s initial Business Combination for specific uses as designated therein. The January 2024 Promissory Note does not bear interest, matures on the date of consummation of the Business Combination and is subject to customary events of default. The principal amount under the January 2024 Promissory Note will be paid at the closing of the Business Combination from the funds that ESGEN has available to it outside of its Trust Account (See Note 10).

 

F-15

 

 

Due to Related Party

 

In the ordinary course of business, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may pay for certain expenses on behalf of the Company. These amounts paid for on behalf of the Company are due upon demand and are non-interest bearing. At December 31, 2023 and 2022, $75,000 and $0, respectively, is included in due to related party on the balance sheet for expenses the Sponsor paid for on behalf of the company. Including the amounts paid for by the Sponsor and the office space, utilities, secretarial support and administrative services (discussed below), the aggregate amount for due to related party on the balance sheet was $339,193 and $144,193 at December 31, 2023 and 2022, respectively.

 

Working Capital Loans

 

In order to finance transaction costs in connection with an intended Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes the initial Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.00 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. As of December 31, 2023 and 2022, the Company had no borrowings under the Working Capital Loans.

 

Office Space, Secretarial and Administrative Services

 

Through the earlier of consummation of the initial Business Combination and the liquidation, the Company incurs $10,000 per month for office space, utilities, secretarial support and administrative services provided by the Sponsor. For each of the years ended December 31, 2023 and 2022, the Company incurred $120,000. No amounts have been paid for these services. As of December 31, 2023 and 2022, the Company has accrued and reported on the balance sheets $264,193 and $144,193, respectively, pursuant to this agreement, and included in “Due to related party”.

 

Note 4 - Prepaid Expenses

 

The Company’s prepaid expenses as of December 31, 2023 and 2022 primarily consisted of the following:

 

   December 31,
2023
   December 31,
2022
 
Prepaid insurance  $17,421   $26,081 
Other prepaid expenses   1,858    5,029 
   $19,279   $31,110 

 

F-16

 

 

Note 5 - Accounts Payable and Accrued Expense

 

The Company’s accounts payable and accrued expenses as of December 31, 2023 and 2022 primarily consisted of legal accruals.

 

   December 31,
2023
   December 31,
2022
 
Legal accrual  $5,534,483   $1,705,049 
Other payables and expenses   134,866    161,943 
   $5,669,349   $1,866,992 

 

Note 6 - Commitments & Contingencies

 

Registration and Shareholder Rights

 

The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and expected shareholder rights agreement signed at the closing of our Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s completion of its initial Business Combination. However, the registration and expected shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lock-up period, which occurs (i) in the case of the Founder Shares, and (ii) in the case of the private placement warrants and the respective Class A ordinary shares issuable upon exercise of the private placement warrants, 30 days after the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans (and any Class A ordinary shares issuable upon the exercise of the Working Capital Loans and warrants that may be issued upon conversion of Working Capital Loans) will be entitled to registration rights pursuant to a registration and expected shareholder rights agreement signed at the closing of our Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company’s register such securities.

 

In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of its initial Business Combination. However, the registration and expected shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lockup period, which occurs (i) in the case of the Founder Shares, as described in the following paragraph, and (ii) in the case of the Private Placement Warrants and the respective Class A ordinary shares underlying such warrants, 30 days after the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

 

Except as described herein, the Sponsor and its directors and executive officers have agreed not to transfer, assign or sell any of their Founder Shares until the earliest of (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the closing price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company complete a liquidation, merger, share exchange or other similar transaction that results in all of the public shareholders having the right to exchange their ordinary shares for cash, securities or other property. Any permitted transferees would be subject to the same restrictions and other agreements of the Sponsor and its directors and executive officers with respect to any founder shares. Any permitted transferees will be subject to the same restrictions and other agreements of the Sponsor with respect to any Founder Shares. The Company refers to such transfer restrictions throughout the Public Offering as the lock- up.

 

F-17

 

 

In addition, pursuant to the registration and expected shareholder rights agreement, the Sponsor, upon and following consummation of an initial Business Combination, will be entitled to nominate three individuals for election to the board of directors, as long as the Sponsor holds any securities covered by the registration and expected shareholder rights agreement.

 

Underwriting Agreement

 

The underwriters were entitled to a deferred underwriters fee of 3.5% of the gross proceeds of the Public Offering upon the completion of the Company’s initial Business Combination. In April 2023, the underwriters waived any right to receive the deferred underwriters fee and will therefore receive no additional underwriters fee in connection with the Closing. As a result, the Company recognized $425,040 of other income on the statement of operations and $9,234,960 was recorded to accumulated deficit on the statements of changes in redeemable ordinary shares and shareholders’ deficit in relation to the reduction of the deferred underwriters fee. As of December 31, 2023 and 2022, the deferred underwriters fee is $0 and $9,660,000, respectively.

 

To account for the waiver of the deferred underwriters fee, the Company analogized to the SEC staff’s guidance on accounting for reducing a liability for “trailing fees”. Upon the waiver of the deferred underwriters fee, the Company reduced the deferred underwriters fee to $0 and reversed the previously recorded cost of issuing the instruments in the IPO, which included recognizing a contra-expense of $425,040, which is the amount previously allocated to liability classified warrants and expensed upon the IPO, and reduced the accumulated deficit and increased income available to Class B ordinary shares by $9,234,960, which was previously allocated to the Class A ordinary shares subject to redemption and accretion recognized at the IPO date. Additionally, as the amount is a component of accretion of Class A ordinary shares subject to possible redemption, the Company treated it in the same manner as a dividend paid to the shareholder in the calculation of the net (loss) income per ordinary share.

 

Business Combination

 

On April 19, 2023, the Company entered into a Business Combination Agreement, by and among the Company, ESGEN OpCo, LLC, a Delaware limited liability company and wholly-owned subsidiary of ESGEN (“OpCo”), Sunergy Renewables, LLC, a Nevada limited liability company (“Sunergy”), the Sunergy equity holders set forth on the signature pages thereto (collectively, “Sellers” and each, a “Seller”, and collectively with Sunergy, the “Sunergy Parties”), for limited purposes, the Sponsor, and for limited purposes, Timothy Bridgewater, an individual, in his capacity as the Sellers Representative (the “Business Combination Agreement”). The Company consummated the Business Combination on March 13, 2024 (see Note 10 – Subsequent Events)

 

Note 7 - Warrant Liabilities

 

The Company accounts for the 27,840,000 warrants issued in connection with the IPO (13,800,000 Public Warrants and 14,040,000 Private Placement Warrants) in accordance with the guidance contained in ASC Topic 815-40. Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly, the Company classifies each warrant as a liability at its fair value. This liability is subject to remeasurement at each balance sheet date.

 

With each such remeasurement, the warrant liabilities will be adjusted to fair value, with the change in fair value recognized in the Company’s statements of operations.

 

F-18

 

 

Public Warrants

 

Each whole warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment as discussed herein. In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described adjacent to “Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described adjacent to the caption “Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price.

 

The warrants will become exercisable 30 days after the completion of the Company’s initial Business Combination and will expire five years after the completion of the Company’s initial Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.

 

The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of the initial Business Combination, it will use its commercially reasonable efforts to file with the SEC a post-effective amendment to the registration statement of which this prospectus forms a part or a new registration statement for the registration, under the Securities Act, of the Class A ordinary shares issuable upon exercise of the warrants, and the Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and a current prospectus relating to those Class A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elect, it will not be required to file or maintain in effect a registration statement, but the Company will use its commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. The “fair market value” as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption, but it will use its commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class A ordinary shares equal to the lesser of (A) the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the “fair market value” (defined below) less the exercise price of the warrants by (y) the fair market value and (B) 0.361. The “fair market value” as used in this paragraph shall mean the volume weighted average price of the Class A ordinary shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. 

 

Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00. Once the warrants become exercisable, the Company may redeem not less than all of the outstanding warrants (except as described herein with respect to the Private Placement Warrants):

 

  in whole and not in part;

 

  at a price of $0.01 per warrant;

 

  upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and

 

F-19

 

 

  if, and only if, the closing price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “Description of Securities- Warrants-Public Shareholders’ Warrants-Anti-dilution Adjustments”) for any 20 trading days within a 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders.

 

Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00. Once the warrants become exercisable, the Company may redeem not less than all of the outstanding warrants:

 

  in whole and not in part;

 

  at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption; and

 

  if, and only if, the closing price of the Class A ordinary shares equals or exceeds $10.00 per public share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “Description of Securities- Warrants-Public Shareholders’ Warrants-Anti-dilution Adjustments”) for any 20 trading days within the 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders;

 

Private Warrants

 

If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the units sold in the Public Offering. Any amendment to the terms of the Private Placement Warrants or any provision of the warrant agreement with respect to the Private Placement Warrants will require a vote of holders of at least 50% of the number of the then outstanding Private Placement Warrants.

 

The accounting treatment of derivative financial instruments requires that the Company record a derivative liability upon the closing of the IPO. Accordingly, the Company has classified each warrant as a liability at its fair value and the warrants were allocated a portion of the proceeds from the issuance of the Units equal to its fair value. These liabilities are subject tore-measurement at each balance sheet date. With each such re-measurement, the warrant liabilities will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations. The Company will reassess the classification at each balance sheet date. If the classification changes as a result of events during the period, the warrants will be reclassified as of the date of the event that causes the reclassification.

 

Note 8 - Recurring Fair Value Measurements

 

As of December 31, 2023 and 2022, marketable securities and cash held in Trust Account are determined by Level 1 inputs utilizing quoted prices (unadjusted) in active markets for identical assets.

 

The Company’s Public Warrants are traded on the Nasdaq. As such, the Public Warrant valuation is based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. The fair value of the Public Warrant liabilities is classified within Level 1 of the fair value hierarchy.

 

At December 31, 2023 and 2022, the Company considers the Private Warrants to be economically equivalent to the Public Warrants. As such, the valuation of the Public Warrants was used to value the Private Warrants. The fair value of the Private Warrant liabilities is classified within Level 2 of the fair value hierarchy.

 

The following tables presents fair value information as of December 31, 2023 and 2022 of the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value.

 

   December 31, 2023 
   Level 1   Level 2   Level 3   Total 
Assets:                
Cash held in Trust Account  $16,018,732   $
-
   $
-
   $16,018,732 
Liabilities:                    
Public Warrants   552,000    
-
    
-
    552,000 
Private Warrants   
-
    561,600    
-
    561,600 
Total liabilities  $552,000   $561,600   $
-
   $1,113,600 

 

F-20

 

 

   December 31, 2022 
   Level 1   Level 2   Level 3   Total 
Assets:                
Marketable securities held in Trust Account  $285,506,568   $
-
   $
-
   $285,506,568 
Liabilities:                    
Public Warrants  $394,680   $
-
   $
-
   $394,680 
Private Warrants   
-
    401,544    
-
    401,544 
Total liabilities  $394,680   $401,544   $
-
   $796,224 

 

There were no transfers to or from Levels 1, 2 or 3 for the year ended December 31, 2023 or 2022.

 

Note 9 - Shareholders’ Deficit

 

Preference shares- The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of December 31, 2023 and 2022, there were no preference shares issued or outstanding.

 

Class A ordinary shares- The Company is authorized to issue 250,000,000 Class A ordinary shares with a par value of $0.0001 per share. As of December 31, 2023 and 2022, there were 5,619,077 and 0 Class A ordinary shares issued or outstanding other than the 1,408,555 and 27,600,000 Class A ordinary shares subject to possible redemption that are accounted for outside of the shareholders’ deficit section of the balance sheets, respectively.

 

In connection with the approval of the Conversion Proposal at the October 20, 2023 shareholder meeting and the adoption of the Charter Amendment, the Sponsor converted all of its 5,619,077 Class B ordinary shares into Class A ordinary shares. As a result of the Sponsor Share Conversion and redemptions made in connection with the Extension Proposal and Conversion Proposal, 1,408,555 and 5,619,077 redeemable Class A ordinary shares and non-redeemable Class A ordinary shares, respectively, remain outstanding. Notwithstanding the Sponsor Share Conversion, the Sponsor will be not entitled to receive any funds held in the Trust Account with respect to any Class A ordinary shares issued to the Sponsor as a result of the Sponsor Share Conversion and no additional amounts will be deposited into the Trust Account in respect of shares of Class A ordinary shares held by the Sponsor in connection with the extension of the Termination Date to the Extended Date or any Additional Extension Dates.

 

Class B ordinary shares- The Company is authorized to issue 25,000,000 Class B ordinary shares with a par value of $0.0001 per share. Holders are entitled to one vote for each share of Class B ordinary shares. As of December 31, 2023 and 2022, there were 1,280,923 and 6,900,000 Class B ordinary shares issued and outstanding, respectively.

 

Holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company’s shareholders except as required by law. Unless specified in the Company’s amended and restated memorandum and articles of association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the Company’s ordinary shares that are voted is required to approve any such matter voted on by its shareholders.

 

The Class B ordinary shares will automatically convert into Class A ordinary shares (which such Class A ordinary shares delivered upon conversion will not have any redemption rights or be entitled to liquidating distributions from the Trust Account if the Company fails to consummate an initial Business Combination) at the time of the initial Business Combination or earlier at the option of the holders thereof at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion of the Public Offering, plus (ii) the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor, any of its affiliates or any members of the Company’s management team upon conversion of Working Capital Loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than one-to-one.

 

This is different than some other similarly structured blank check companies in which the initial shareholders will only be issued an aggregate of 20% of the total number of shares to be outstanding prior to the initial Business Combination.

 

F-21

 

 

Note 10 - Subsequent Events

 

On each of January 18, 2024 and February 16, 2024, the Company deposited $24,650 into the Trust Account in connection with Additional Extensions.

 

First Amendment to the Business Combination Agreement

 

On January 24, 2024, ESGEN and Sunergy entered into the First Amendment to the Initial Business Combination Agreement (the “First Amendment” and, the Initial Business Combination Agreement as amended by the First Amendment, the “Business Combination Agreement”). The First Amendment provides for, among other things, the:

 

(i) reduction of the aggregate consideration to the pre-transaction Sunergy equity holders from $410 million to $337.3 million;

 

(ii) removal of the (a) $20 million minimum cash condition and (b) provision requiring forfeiture of founder shares in connection with excess transaction expenses;

 

(iii) modification of the terms and structure of the Sponsor PIPE Investment (as defined below) from $10.0 million in shares of Class A common stock, par value $0.0001 per share (“New PubCo Class A Common Stock”), of the continuing entity following the continuation of ESGEN by way of domestication of ESGEN into a Delaware corporation, which continuing entity will be renamed Zeo Energy Corp. (“New PubCo”), to up to $15.0 million in convertible preferred units of OpCo (the “Convertible OpCo Preferred Units”) to be issued to the Sponsor pursuant to the Amended and Restated Subscription Agreement (as defined below);

 

(iv) forfeiture of an aggregate of 2.9 million founder shares and an additional 500,000 founder shares if, within two years of closing of the Business Combination (the “Closing”), the Convertible OpCo Preferred Units are redeemed or converted (with such shares subject to a lock-up for two years after the Closing);

 

(v) forfeiture of all private warrants to purchase one ESGEN Class A ordinary share, par value $0.0001 per share, of ESGEN (“ESGEN Private Placement Warrants”);

 

(vi) Sponsor will contribute those certain promissory notes, dated as of April 27, 2021 and October 17, 2023 (which promissory note amended and restated that certain promissory note dated as of April 5, 2023), by and between Sponsor and ESGEN, to ESGEN as a contribution to the capital of ESGEN and all amounts due thereunder will be cancelled; and

 

(vii) the outside date for the Business Combination to be extended to April 22, 2024.

 

Non-redemption Agreement

 

On March 11, 2024, ESGEN, entered into a non-redemption agreement (the “Non-Redemption Agreement”) with The K2 Principal Fund L.P. (“K2”), pursuant to which K2 agreed (i) to purchase at least 174,826 of ESGEN’s Class A ordinary shares, par value $0.0001 per share (the “Class A ordinary shares”), in the open market from investors who had elected to redeem such shares in connection with the Company’s extraordinary general meeting of shareholders held to approve the proposed Business Combination Agreement.

 

In exchange for the foregoing commitments to purchase and not redeem such Class A ordinary shares, ESGEN agreed to issue, for no consideration an aggregate of 225,174 shares of Class A common stock, par value $0.0001 per share, of Zeo Energy Corp., a Delaware corporation and the successor to ESGEN following the close of the Business Combination Agreement.

 

F-22

 

 

Business Combination

 

On March 13, 2024 (the “Closing Date”), the registrant consummated its previously announced business combination (the “Closing”), pursuant to that certain Business Combination Agreement, dated as of April 19, 2023 (as amended on January 24, 2024, the “Business Combination Agreement”), by and among Zeo Energy Corp., a Delaware corporation (f/k/a ESGEN Acquisition Corporation, a Cayman Islands exempted company), ESGEN OpCo, LLC, a Delaware limited liability company(“OpCo”), Sunergy Renewables, LLC, a Nevada limited liability company (“Sunergy”), the Sunergy equityholders set forth on the signature pages thereto or joined thereto (collectively, “Sellers” and each, a “Seller”, and collectively with Sunergy, the “Sunergy Parties”), for limited purposes, ESGEN LLC, a Delaware limited liability company (the “Sponsor”), and for limited purposes, Timothy Bridgewater, an individual, in his capacity as the Sellers Representative (collectively, the “Business Combination”). Prior to the Closing, (i) except as otherwise specified in the Business Combination Agreement, each issued and outstanding Class B ordinary share of ESGEN was converted into one Class A ordinary share of ESGEN (the “ESGEN Class A Ordinary Shares” and such conversion, the “ESGEN Share Conversion”); and (ii) ESGEN was domesticated into the State of Delaware so as to become a Delaware corporation (the “Domestication”). In connection with the Closing, the registrant changed its name from “ESGEN Acquisition Corporation” to “Zeo Energy Corp.”

 

In connection with entering into the Business Combination Agreement, ESGEN and the Sponsor entered into a subscription agreement, dated April 19, 2023, which ESGEN, the Sponsor and OpCo subsequently amended and restated on January 24, 2024 (the “Sponsor Subscription Agreement”), pursuant to which, among other things, the Sponsor agreed to purchase an aggregate of 1,000,000 preferred units of OpCo (“Convertible OpCo Preferred Units”) convertible into Exchangeable OpCo Unites (as defined below) (and be issued an equal number of shares of Zeo Class V Common Stock) concurrently with the Closing at a cash purchase price of $10.00 per unit and up to an additional 500,000 Convertible OpCo Preferred Units (together with the concurrent issuance of an equal number of shares of Zeo Class V Common Stock) during the six months after Closing if called for by Zeo. Prior to the Closing, ESGEN informed the Sponsor that it wished to call for the additional 500,000 Convertible OpCo Preferred Units at the Closing and, as a result, a total of 1,500,00 Convertible OpCo Preferred Units and an equal number of shares of Zeo Class V Common Stock were issued to Sponsor pursuant to the Sponsor Subscription Agreement for aggregate consideration of $15,000,000.

 

F-23

 

 

27600000 3884888 0.44 1.32 6900000 6900000 0.29 0.30 0.29 0.30 0.44 1.32 150000 true FY 0001865506 0001865506 2023-01-01 2023-12-31 0001865506 us-gaap:CommonClassAMember 2023-01-01 2023-12-31 0001865506 esac:WarrantsEachExercisableForOneShareOfClassACommonStockAtAPriceOfElevenPointFiveZeroSubjectToAdjustmentMember 2023-01-01 2023-12-31 0001865506 2023-06-30 0001865506 us-gaap:CommonClassAMember 2024-03-25 0001865506 esac:ClassVCommonStockMember 2024-03-25 0001865506 2023-12-31 0001865506 2022-12-31 0001865506 us-gaap:RelatedPartyMember 2023-12-31 0001865506 us-gaap:RelatedPartyMember 2022-12-31 0001865506 us-gaap:CommonClassAMember 2023-12-31 0001865506 us-gaap:CommonClassAMember 2022-12-31 0001865506 us-gaap:CommonClassBMember 2023-12-31 0001865506 us-gaap:CommonClassBMember 2022-12-31 0001865506 2022-01-01 2022-12-31 0001865506 esac:RedeemableClassAOrdinarySharesMember 2023-01-01 2023-12-31 0001865506 esac:RedeemableClassAOrdinarySharesMember 2022-01-01 2022-12-31 0001865506 esac:NonRedeemableClassAAndClassBOrdinarySharesMember 2023-01-01 2023-12-31 0001865506 esac:NonRedeemableClassAAndClassBOrdinarySharesMember 2022-01-01 2022-12-31 0001865506 us-gaap:CommonClassAMember esac:OrdinaryShareSubjectToPossibleRedemptionMember 2021-12-31 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001865506 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001865506 us-gaap:RetainedEarningsMember 2021-12-31 0001865506 2021-12-31 0001865506 us-gaap:CommonClassAMember esac:OrdinaryShareSubjectToPossibleRedemptionMember 2022-01-01 2022-12-31 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001865506 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001865506 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001865506 us-gaap:CommonClassAMember esac:OrdinaryShareSubjectToPossibleRedemptionMember 2022-12-31 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-12-31 0001865506 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001865506 us-gaap:RetainedEarningsMember 2022-12-31 0001865506 us-gaap:CommonClassAMember esac:OrdinaryShareSubjectToPossibleRedemptionMember 2023-01-01 2023-12-31 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001865506 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001865506 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001865506 us-gaap:CommonClassAMember esac:OrdinaryShareSubjectToPossibleRedemptionMember 2023-12-31 0001865506 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-12-31 0001865506 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-12-31 0001865506 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001865506 us-gaap:RetainedEarningsMember 2023-12-31 0001865506 us-gaap:IPOMember 2021-10-22 2021-10-22 0001865506 us-gaap:OverAllotmentOptionMember 2021-10-22 0001865506 esac:PrivatePlacementWarrantsMember us-gaap:IPOMember 2021-10-22 0001865506 esac:PrivatePlacementWarrantsMember 2023-01-01 2023-12-31 0001865506 us-gaap:IPOMember 2021-10-22 0001865506 esac:InitialBusinessCombinationMember 2023-01-01 2023-12-31 0001865506 esac:PublicWarrantsMember us-gaap:IPOMember 2023-12-31 0001865506 2023-01-18 0001865506 us-gaap:CommonClassAMember 2023-01-18 2023-01-18 0001865506 us-gaap:CommonClassAMember 2023-01-18 0001865506 2023-01-18 2023-01-18 0001865506 esac:SponsorMember 2023-01-01 2023-12-31 0001865506 us-gaap:IPOMember 2023-12-31 0001865506 2023-10-20 0001865506 us-gaap:CommonClassBMember 2023-10-20 0001865506 us-gaap:CommonClassAMember 2023-10-20 0001865506 us-gaap:CommonClassAMember esac:SponsorMember 2023-12-31 0001865506 us-gaap:CommonClassAMember esac:FounderSharesMember 2023-12-31 0001865506 us-gaap:CashMember 2023-12-31 0001865506 us-gaap:AccountsPayableMember 2023-12-31 0001865506 esac:ClassAOrdinarySharesSubjectToPossibleRedemptionMember 2023-01-01 2023-12-31 0001865506 esac:IncomeTaxesBenefitsMember 2023-12-31 0001865506 esac:IncomeTaxesBenefitsMember 2022-12-31 0001865506 esac:PromissoryNoteWithRelatedPartyMember 2021-04-27 0001865506 esac:PromissoryNoteWithRelatedPartyMember 2023-12-31 0001865506 esac:PromissoryNoteWithRelatedPartyMember 2022-12-31 0001865506 esac:UnsecuredPromissoryNoteMember 2023-04-05 0001865506 esac:OctoberTwoThousandTwentyThreePromissoryNoteMember 2023-10-17 0001865506 esac:OctoberTwoThousandTwentyThreePromissoryNoteMember 2023-10-31 0001865506 esac:OctoberTwoThousandTwentyThreePromissoryNoteMember 2023-12-31 0001865506 srt:ScenarioForecastMember esac:JanuaryTwoThousandTwentyFourPromissoryNoteMember 2024-01-24 0001865506 esac:WorkingCapitalLoansWarrantMember 2023-12-31 0001865506 esac:WorkingCapitalLoansWarrantMember 2022-12-31 0001865506 esac:OfficeSpaceSecretarialAndAdministrativeServicesMember us-gaap:RelatedPartyMember 2023-12-31 0001865506 esac:OfficeSpaceSecretarialAndAdministrativeServicesMember us-gaap:RelatedPartyMember 2022-12-31 0001865506 esac:SponsorMember us-gaap:CommonClassAMember esac:PrivatePlacementWarrantsMember 2023-01-01 2023-12-31 0001865506 esac:SponsorMember us-gaap:CommonClassAMember 2023-01-01 2023-12-31 0001865506 us-gaap:IPOMember 2023-01-01 2023-12-31 0001865506 us-gaap:CommonClassBMember 2023-01-01 2023-12-31 0001865506 esac:BusinessCombinationAgreementMember 2023-01-01 2023-12-31 0001865506 esac:PublicWarrantsMember 2023-12-31 0001865506 esac:PrivateWarrantsMember 2023-12-31 0001865506 us-gaap:CommonClassAMember esac:PublicWarrantsMember 2023-12-31 0001865506 us-gaap:CommonStockMember esac:PublicWarrantsMember 2023-12-31 0001865506 esac:InitialBusinessCombinationMember 2023-12-31 0001865506 esac:PublicWarrantsMember 2023-12-31 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceedsEighteenPointZeroZeroMember 2023-12-31 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceedsEighteenPointZeroZeroMember 2023-01-01 2023-12-31 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceedsEighteenPointZeroZeroMember us-gaap:CommonClassAMember 2023-12-31 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceedsTenPointZeroZeroMember us-gaap:CommonClassAMember 2023-12-31 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceedsTenPointZeroZeroMember 2023-12-31 0001865506 esac:RedemptionOfWarrantPricePerShareEqualsOrExceedsTenPointZeroZeroMember 2023-01-01 2023-12-31 0001865506 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001865506 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001865506 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001865506 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001865506 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001865506 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember esac:PublicWarrantsMember 2023-12-31 0001865506 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember esac:PublicWarrantsMember 2023-12-31 0001865506 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember esac:PublicWarrantsMember 2023-12-31 0001865506 us-gaap:FairValueMeasurementsRecurringMember esac:PublicWarrantsMember 2023-12-31 0001865506 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember esac:PrivateWarrantsMember 2023-12-31 0001865506 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember esac:PrivateWarrantsMember 2023-12-31 0001865506 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember esac:PrivateWarrantsMember 2023-12-31 0001865506 us-gaap:FairValueMeasurementsRecurringMember esac:PrivateWarrantsMember 2023-12-31 0001865506 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001865506 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001865506 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001865506 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001865506 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember esac:PublicWarrantsMember 2022-12-31 0001865506 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember esac:PublicWarrantsMember 2022-12-31 0001865506 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember esac:PublicWarrantsMember 2022-12-31 0001865506 us-gaap:FairValueMeasurementsRecurringMember esac:PublicWarrantsMember 2022-12-31 0001865506 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember esac:PrivateWarrantsMember 2022-12-31 0001865506 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember esac:PrivateWarrantsMember 2022-12-31 0001865506 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember esac:PrivateWarrantsMember 2022-12-31 0001865506 us-gaap:FairValueMeasurementsRecurringMember esac:PrivateWarrantsMember 2022-12-31 0001865506 us-gaap:CommonClassBMember 2023-10-20 2023-10-20 0001865506 us-gaap:CommonClassAMember 2023-10-20 2023-10-20 0001865506 esac:NonredeemableClassAOrdinarySharesMember 2023-10-20 2023-10-20 0001865506 us-gaap:SubsequentEventMember 2024-01-18 0001865506 us-gaap:SubsequentEventMember 2024-02-16 0001865506 esac:BusinessCombinationAgreementMember us-gaap:SubsequentEventMember 2024-01-24 2024-01-24 0001865506 us-gaap:SubsequentEventMember 2024-01-24 2024-01-24 0001865506 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2024-01-24 0001865506 us-gaap:SubsequentEventMember 2024-01-24 0001865506 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2024-03-11 2024-03-11 0001865506 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2024-03-11 0001865506 esac:SponsorMember us-gaap:SubsequentEventMember 2024-01-24 0001865506 esac:ClassVCommonStockMember us-gaap:SubsequentEventMember 2024-01-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure esac:Days